



RECEIVED

DEC 12 2002

TECH CENTER 1600/2900 PATENT

*Handwritten:* #20, 1/9/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of : **Attorney Docket No.: 6056-257**  
Keith R. McCrae :  
Serial No.: 09/437,912 : Group Art Unit: 1653  
Filing Date: November 9, 1999 : Examiner: Hope A. Robinson  
For: **INHIBITION OF ANGIOGENESIS** :  
**BY HIGH MOLECULAR WEIGHT** :  
**KININOGEN PEPTIDE ANALOGS** :  
**THEREOF** :

AMENDMENT

Commissioner for Patents  
Washington, D.C. 20231  
Box Fee Amendment

Sir:

This is in response to the Office Action, dated August 9, 2002 (Paper No. 18). Per the petition and fee submitted herewith, applicant invokes the benefit of 37 CFR 1.136 to secure a one-month extension of time up to and including December 9, 2002.

Kindly amend the application without prejudice as follows.

Please rewrite the following claims. A mark-up of the amended claims is contained in Appendix A hereto.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)	
I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.	
BY	<u>Dee Naticchia</u>
DATE:	<u>12/3/02</u>

C1

19. (amended) A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of a two-chain high molecular weight kininogen.

C2

22. (amended) A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of a single-chain high molecular weight kininogen.

C3

30. (amended) A compound of the formula  $X_1$ -His-Lys-X-Lys- $X_2$  wherein  
X is any amino acid,  
 $X_1$  is  
the segment His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly (SEQ ID NO:1), or N-terminal truncation fragment thereof containing at least one amino acid, and  
 $X_2$  is  
(i) zero amino acids, or  
(ii) the segment Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:2), or C-terminal truncation fragment thereof containing at least one amino acid,  
and wherein said compound optionally comprises an amino-terminal protecting group and optionally comprises a carboxy-terminal protecting group.

C4  
5/04

34. (amended) A compound having the amino acid sequence Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn (SEQ ID NO:8).

35. (amended) A compound having the amino acid sequence His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:9).

C5

41. (amended) The method of claim 16, wherein the compound has at least 30% amino acid sequence homology to the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:5).